Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

57.94  -1.73 (-2.9%)

After market: 57.94 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ANIP. ANIP was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on ANIP.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ANIP had positive earnings in the past year.
In the past year ANIP had a positive cash flow from operations.
In multiple years ANIP reported negative net income over the last 5 years.
ANIP had a positive operating cash flow in 4 of the past 5 years.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

1.2 Ratios

With an excellent Return On Assets value of 0.59%, ANIP belongs to the best of the industry, outperforming 82.70% of the companies in the same industry.
The Return On Equity of ANIP (1.75%) is better than 83.24% of its industry peers.
ANIP has a better Return On Invested Capital (1.53%) than 78.38% of its industry peers.
Industry RankSector Rank
ROA 0.59%
ROE 1.75%
ROIC 1.53%
ROA(3y)-3.45%
ROA(5y)-2.78%
ROE(3y)-7.72%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 10 -10

1.3 Margins

The Profit Margin of ANIP (1.09%) is better than 82.70% of its industry peers.
In the last couple of years the Profit Margin of ANIP has declined.
ANIP's Operating Margin of 3.07% is fine compared to the rest of the industry. ANIP outperforms 78.38% of its industry peers.
In the last couple of years the Operating Margin of ANIP has declined.
ANIP has a Gross Margin of 60.67%. This is in the better half of the industry: ANIP outperforms 67.57% of its industry peers.
In the last couple of years the Gross Margin of ANIP has remained more or less at the same level.
Industry RankSector Rank
OM 3.07%
PM (TTM) 1.09%
GM 60.67%
OM growth 3YN/A
OM growth 5Y-10.86%
PM growth 3YN/A
PM growth 5Y-15.97%
GM growth 3Y2.53%
GM growth 5Y-0.34%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ANIP is destroying value.
ANIP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ANIP has been increased compared to 5 years ago.
Compared to 1 year ago, ANIP has an improved debt to assets ratio.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.68, we must say that ANIP is in the distress zone and has some risk of bankruptcy.
ANIP's Altman-Z score of 1.68 is fine compared to the rest of the industry. ANIP outperforms 65.41% of its industry peers.
The Debt to FCF ratio of ANIP is 8.15, which is on the high side as it means it would take ANIP, 8.15 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 8.15, ANIP belongs to the top of the industry, outperforming 83.24% of the companies in the same industry.
A Debt/Equity ratio of 1.44 is on the high side and indicates that ANIP has dependencies on debt financing.
With a Debt to Equity ratio value of 1.44, ANIP is not doing good in the industry: 76.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF 8.15
Altman-Z 1.68
ROIC/WACC0.15
WACC10.36%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

ANIP has a Current Ratio of 2.74. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
ANIP has a Current ratio (2.74) which is comparable to the rest of the industry.
ANIP has a Quick Ratio of 1.97. This is a normal value and indicates that ANIP is financially healthy and should not expect problems in meeting its short term obligations.
ANIP has a Quick ratio (1.97) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 1.97
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ANIP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.01%.
ANIP shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.38% yearly.
ANIP shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.21%.
The Revenue has been growing by 19.28% on average over the past years. This is quite good.
EPS 1Y (TTM)2.01%
EPS 3Y10.48%
EPS 5Y-1.38%
EPS Q2Q%5.51%
Revenue 1Y (TTM)54.21%
Revenue growth 3Y32.66%
Revenue growth 5Y19.28%
Sales Q2Q%12.52%

3.2 Future

The Earnings Per Share is expected to grow by 11.79% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.14% on average over the next years. This is quite good.
EPS Next Y8.19%
EPS Next 2Y9.6%
EPS Next 3Y12.55%
EPS Next 5Y11.79%
Revenue Next Year25.55%
Revenue Next 2Y23.23%
Revenue Next 3Y17.49%
Revenue Next 5Y12.14%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.68 indicates a correct valuation of ANIP.
90.81% of the companies in the same industry are more expensive than ANIP, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.63. ANIP is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 10.22, the valuation of ANIP can be described as reasonable.
Based on the Price/Forward Earnings ratio, ANIP is valued cheaply inside the industry as 88.11% of the companies are valued more expensively.
ANIP is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.68
Fwd PE 10.22
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

80.00% of the companies in the same industry are more expensive than ANIP, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 87.57% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.86
EV/EBITDA 21.05
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ANIP's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ANIP has a very decent profitability rating, which may justify a higher PE ratio.
ANIP's earnings are expected to grow with 12.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.55
PEG (5Y)N/A
EPS Next 2Y9.6%
EPS Next 3Y12.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (2/21/2025, 8:01:14 PM)

After market: 57.94 0 (0%)

57.94

-1.73 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)02-28 2025-02-28/bmo
Inst Owners95.29%
Inst Owner Change1.36%
Ins Owners6.75%
Ins Owner Change-0.71%
Market Cap1.22B
Analysts83.64
Price Target77.11 (33.09%)
Short Float %13.07%
Short Ratio10.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP21.55%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.12%
Min EPS beat(2)5.26%
Max EPS beat(2)20.97%
EPS beat(4)4
Avg EPS beat(4)15%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)53.64%
EPS beat(12)9
Avg EPS beat(12)12.18%
EPS beat(16)11
Avg EPS beat(16)13.14%
Revenue beat(2)2
Avg Revenue beat(2)2.81%
Min Revenue beat(2)0.74%
Max Revenue beat(2)4.87%
Revenue beat(4)4
Avg Revenue beat(4)4.53%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.91%
Revenue beat(8)8
Avg Revenue beat(8)10.25%
Revenue beat(12)11
Avg Revenue beat(12)7.57%
Revenue beat(16)14
Avg Revenue beat(16)6.91%
PT rev (1m)0%
PT rev (3m)-5.5%
EPS NQ rev (1m)-1.31%
EPS NQ rev (3m)17.82%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)24.87%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.5%
Valuation
Industry RankSector Rank
PE 12.68
Fwd PE 10.22
P/S 1.76
P/FCF 15.86
P/OCF 13.11
P/B 2.83
P/tB N/A
EV/EBITDA 21.05
EPS(TTM)4.57
EY7.89%
EPS(NY)5.67
Fwd EY9.79%
FCF(TTM)3.65
FCFY6.3%
OCF(TTM)4.42
OCFY7.63%
SpS32.96
BVpS20.49
TBVpS-9.49
PEG (NY)1.55
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.59%
ROE 1.75%
ROCE 1.94%
ROIC 1.53%
ROICexc 1.78%
ROICexgc 5.36%
OM 3.07%
PM (TTM) 1.09%
GM 60.67%
FCFM 11.08%
ROA(3y)-3.45%
ROA(5y)-2.78%
ROE(3y)-7.72%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-40.21%
ROICexc growth 3YN/A
ROICexc growth 5Y-10.91%
OM growth 3YN/A
OM growth 5Y-10.86%
PM growth 3YN/A
PM growth 5Y-15.97%
GM growth 3Y2.53%
GM growth 5Y-0.34%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.44
Debt/FCF 8.15
Debt/EBITDA 7.57
Cap/Depr 26.72%
Cap/Sales 2.33%
Interest Coverage 0.78
Cash Conversion 113.8%
Profit Quality 1018.79%
Current Ratio 2.74
Quick Ratio 1.97
Altman-Z 1.68
F-Score5
WACC10.36%
ROIC/WACC0.15
Cap/Depr(3y)11.71%
Cap/Depr(5y)12.76%
Cap/Sales(3y)1.94%
Cap/Sales(5y)2.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.01%
EPS 3Y10.48%
EPS 5Y-1.38%
EPS Q2Q%5.51%
EPS Next Y8.19%
EPS Next 2Y9.6%
EPS Next 3Y12.55%
EPS Next 5Y11.79%
Revenue 1Y (TTM)54.21%
Revenue growth 3Y32.66%
Revenue growth 5Y19.28%
Sales Q2Q%12.52%
Revenue Next Year25.55%
Revenue Next 2Y23.23%
Revenue Next 3Y17.49%
Revenue Next 5Y12.14%
EBIT growth 1Y-52.34%
EBIT growth 3YN/A
EBIT growth 5Y6.32%
EBIT Next Year9.84%
EBIT Next 3Y14.51%
EBIT Next 5Y12.11%
FCF growth 1Y270.27%
FCF growth 3Y129.31%
FCF growth 5Y12.41%
OCF growth 1Y338.26%
OCF growth 3Y98.24%
OCF growth 5Y12.14%